m+Medelevator.RU
← Поиск публикаций
European journal of human genetics : EJHG · 2025

Non-isolated tetralogy of fallot (TOF+): exome sequencing efficacy and phenotypic expansions.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Volpi Julia, Zhao Xiaonan, Owen Nichole, Evans Tia, Holder-Espinasse Muriel, Lahiri Nayana, Sherlock Eleanor, Poke Gemma, Breckpot Jeroen, Devriendt Koen, Cools Bjorn, Brusco Alfredo, Ferrero Giovanni Battista, Grosso Enrico, Vasudevan Pradeep, Loddo Sara, Novelli Antonio, Digilio Maria Cristina, Engwerda Aafke, Hitzert Marrit, Male Alison, Bownass Lucy, Newbury-Ecob Ruth, Miedzybrodzka Zosia, Armstrong Ruth, Lynch Sally Ann, Houge Gunnar, Xiong Shiyi, Lalani Seema R, Rosenfeld Jill A, Luna Pamela N, Shaw Chad A, Scott Daryl A

Аннотация

Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart defect (CHD). TOF may present in isolation or in conjunction with one or more non-cardiac congenital anomalies or neurodevelopmental disorders (TOF+). Uncertainty regarding the efficacy of various genetic testing strategies, and an incomplete understanding of the genetic causes of TOF+, may lead to hesitancy in recommending genetic testing, particularly, clinical exome sequencing (cES). Here, we analyzed cES data from 131 individuals with TOF+. A definitive or probable diagnosis was made for 31 individuals, yielding a diagnostic rate of 23.6% (31/131). One individual received three diagnoses. Commercially available CHD panels would have detected only 27.3% (9/33) to 63.6% (21/33) of the diagnoses made by cES. We then used a machine learning approach to identify four genes for which there is sufficient evidence to support a phenotypic expansion including TOF: DVL3, MED13L, PUF60, and MEIS2. Since chromosomal microarray analysis (CMA) has been reported to have a diagnostic efficacy of 10-20% in individuals with TOF, we conclude that cES should be considered for all individuals with TOF+ for whom a molecular diagnosis has not been established by CMA. We also conclude that TOF represents a low penetrance phenotype associated with genetic syndromes caused by pathogenic variants in DVL3, MED13L, PUF60, and MEIS2.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты